Hjerne

Parkinson, årsaker

Parkinson

Pasientinformasjon

Nevrologi

Kliniske kapitler

Håndboken

Norsk Elektronisk Legehåndbok

Hjerneceller og dopamin

Hvorfor dør nevronene?

Parkinsons sykdom versus parkinsonisme

Vil du vite mer?

Parkinsons sykdom (PS)

--&gt; https://nevrologi.legehandboka.no/handboken/sykdomsgrupper/bevegelsesforstyrrelser/sykdommer-og-symptomer/parkinsons-sykdom#kort-om

Mygland Å, et al. Parkinsons sykdom. NEL Nevrologi. Sist revidert 07.11.2017. Sist oppdatert 28. okt. 2022. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=30879893[uid]

GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019. May;18(5):459–480. PMID: 30879893 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Lancet Neurol[ta]+AND+20[vol]+AND+385[page]

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385-397. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=27762639[uid]

Zhang Q, Chen W, Tan S, Lin T. Stem Cells for Modeling and Therapy of Parkinson's Disease. Hum Gene Ther 2017; 28(1): 85-98. pmid:27762639 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=JAMA[ta]+AND+323[vol]+AND+548[page]

Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548-560. 

--&gt; https://archive.org/details/essayonshakingpa00parkuoft/page/n5

Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland, 1817. 

--&gt; https://bestpractice.bmj.com/topics/en-gb/147

Bega D. Parkinson's disease. BMJ Best Practice. Last updated 02.07.2018. 

Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010;16(2):79-84. 

--&gt; http://dx.doi.org/10.1001/jamaneurol.2022.4193

Espay AJ, Okun MS. Abandoning the Proteinopathy Paradigm in Parkinson Disease. JAMA Neurol 2023; 80: 123-124. doi:10.1001/jamaneurol.2022.4193 

--&gt; http://www.uptodate.com/online/content/search.do?search=Etiology and pathogenesis of Parkinson disease

Jankovic J. Etiology and pathogenesis of Parkinson disease. UpToDate, last updated Dec 21, 2021. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=31521533[uid]

Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19(2):170–178. PMID: 31521533 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=19846850[uid]

Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361(17): 1651-61. Pmid: 19846850 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Neurology[ta]+AND+84[vol]+AND+1098[page]

Kenborg L, Rugbjerg K, Lee PC, Ravnskjær L, Christensen J, Ritz B, Lassen CF. Head injury and risk for Parkinson disease: results from a Danish case-control study. Neurology. 2015 Mar 17;84(11):1098-103. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=22083847[uid]

Goldman SM, Quinlan PJ, Ross GW, et al. Solvent exposures and Parkinson disease risk in twins. Ann Neurol 2012; 71(6): 776-84. pmid:22083847 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=36342675[uid]

Schrag A, Bohlken J, Dammertz L, et al. Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. JAMA Neurol. Published online November 07, 2022. PMID: 36342675 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=24894826[uid]

Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol. 2014 Sep;29(9):613-9. Epub 2014 Jun 4. PMID: 24894826. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=J Neurol Neurosurg Psychiatry [ta]+AND+91[vol]+AND+795[page]

Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020; 91:795. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=23250131[uid]

Shen C, Guo Y, Luo W, et al. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 2013; 40(1): 73-9. pmid:23250131 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=26474316[uid]

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30(12): 1591-601. pmid:26474316 

--&gt; http://dx.doi.org/10.4045/tidsskr.22.0804

Dietrichs E, Alves G, Benjaminsen E, et al. Behandling av motoriske symptomer ved Parkinsons sykdom. Tidsskr Nor Legeforen 2023. doi: 10.4045/tidsskr.22.0804 

--&gt; https://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-parkinson-disease#H130396564

Chou KL. Diagnosis and differential diagnosis of Parkinson disease. UpToDate. Sist oppdatert 05.09.2018. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=27435448[uid]

Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, Pellecchia MT, Barone P.. The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. Eur J Neurol. 2016 Nov;23(11):1673-1679 . pmid:27435448 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=33004605[uid]

Scott BM, Eisinger RS, Burns MR, et al. Co-occurrence of apathy and impulse control disorders in Parkinson disease. Neurology. 2020; 95(20) :e2769-e2780. PMID: 33004605 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=26406124[uid]

Egan SJ, Laidlaw K, Starkstein S. Cognitive Behaviour Therapy for Depression and Anxiety in Parkinson's Disease. J Parkinsons Dis 2015; 5(3): 443-51. pmid:26406124 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=31527282[uid]

Hiort YH, Pedersen KF, Dalen I, et al. Orthostatic hypotension in Parkinson disease A 7-year prospective population-based study. Neurology 2019; 93: 1526-34. pmid:31527282 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=24759846[uid]

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014 May 20;82(20):1791-7 . pmid:24759846 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=23279440[uid]

Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS corrected recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013; 20(1): 16-34. pmid:23279440 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=23279439[uid]

Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20(1): 5-15. pmid:23279439 

--&gt; https://helsedirektoratet.no/retningslinjer/aktivitetshandboken-fysisk-aktivitet-i-forebygging-og-behandling

Bahr R, Karlsson J, Ståhle A, et al. Aktivitetshåndboken (IS-1592): Kap. 36: Parkinsons sykdom. Fagbokforlaget: Helsedirektoratet, 2009. 

Tambosco L, Percebois-Macadré L, Rapin A, et al. Effort training in Parkinson's disease: a systematic review. Ann Phys Rehabil Med. 2014 Mar;57(2):79-104. PMID: 24582335 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=25936252[uid]

Uhrbrand A, Stenager E, Pedersen MS, et al. Parkinson's disease and intensive exercise therapy - a systematic review and meta-analysis of randomized controlled trials.. J Neurol Sci. 2015; 353(1-2): 9-19. pmid:25936252 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=24983753[uid]

Shu HF, Yang T, Yu SX, et al. Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.PLoS One. 2014 Jul 1;9(7):e100503. PMID: 24983753. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=26146840[uid]

Roeder L, Costello JT, Smith SS, et al. Effects of Resistance Training on Measures of Muscular Strength in People with Parkinson's Disease: A Systematic Review and Meta-Analysis. PLoS One 2015. pmid:26146840 

--&gt; http://dx.doi.org/10.1002/14651858.CD007830.pub4

Mehrholz J, Kugler J, Storch A, et al. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev. 2015 Aug 22;8:CD007830. DOI: 10.1002/14651858.CD007830.pub4 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=27478953[uid]

Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.. Lancet Neurol. 2016 Aug;15(9):954-66. pmid:27478953 

--&gt; https://www.uptodate.com/contents/pharmacologic-treatment-of-parkinson-disease

Tarsy D. Pharmacologic treatment of Parkinson disease. UpToDate. Literature review current through: Oct 2018. Topic last updated: Jul 10, 2018. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=30574117[uid]

Garcia-Ruiz PJ. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. Front Neurol. 2018;9:1041. Published 2018 Dec 6. PMID: 30574117 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=28861870[uid]

Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf. 2018;41(1):19-75. PMID: 28861870 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=24434037[uid]

Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014; Aug;85. pmid:24434037 

--&gt; http://www.uptodate.com/online/content/search.do?search=Initial pharmacologic treatment of Parkinson disease

Spindler MA, Hurtig HI. Initial pharmacologic treatment of Parkinson disease. UpToDate, last updated Nov 20, 2019. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Neurotherapeutics[ta]+AND+17[vol]+AND+1339[page]

Aradi SD, Hauser RA. Medical Management and Prevention of Motor Complications in Parkinson's Disease. Neurotherapeutics. 2020;17(4):1339-1365. 

Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-6. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=26233582[uid]

Odin P, Ray Chaudhuri K, Slevin JT, et al. National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015 Oct;21(10):1133-44. pmid:26233582 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=32470421[uid]

Vitek JL, Jain R, Chen L, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Lancet Neurol 2020; 19:491. PMID: 32470421 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=25752590[uid]

Lilleeng B, Gjerstad M, Baardsen R, et al. The long-term development of non-motor problems after STN-DBS. Acta Neurol Scand. 2015 Oct;132(4):251-8. pmid:25752590 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=25934016[uid]

Martinez-Fernandez R, Pelissier P, Quesada JL, et al. Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2016; 87(3): 311-8. pmid:25934016 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=30653247[uid]

Seppi K, Ray Chaudhuri K, Coelho M et al. The collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: Mov Disord. 2019 May;34(5):765. PMID: 30653247 

Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; : 10.1212/WNL.0b013e3182516244. 

--&gt; http://www.uptodate.com/online/content/search.do?search=Cognitive impairment and dementia in Parkinson disease

Rodnitzky RL. Cognitive impairment and dementia in Parkinson disease. UpToDate, last updated Apr 15, 2020. 

Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson`s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):767-73. Pmid: 25224676. 

--&gt; https://helsedirektoratet.no/retningslinjer/nasjonal-faglig-retningslinje-om-demens

Nasjonal faglig retningslinje om demens. Helsedirektoratet. Utgitt 18.08.2017. IS-2658. V3.1 publisert 17.12.2017. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Neuropsychopharmacology[ta]+AND+45[vol]+AND+121[page]

Stefani A, Högl B. Sleep in Parkinson's disease. Neuropsychopharmacology. 2020;45(1):121-128. 

Ylikoski A, Martikainen K, Sarkanen T, Partinen M. Parkinson's disease and narcolepsy-like symptoms. Sleepmedicine. Published Online: January 23, 2015 . doi:http://dx.doi.org/10.1016/j.sleep.2014.12.010 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=22942216[uid]

Asahina M, Vichayanrat E, Low DA, et al. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry 2013; 84: 674-80. PMID: 22942216 

Pena JIbarretxe-Bilbao NGarcia-Gorostiaga I, et al. Improving functional disability and cognition in Parkinson disease: Randomized controlled trial. Neurology. 2014 Oct 31. pii: 10.1212/WNL.0000000000001043 . 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=27751556[uid]

Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016; 15(12): 1257-1272. pmid:27751556 

Leung IH, Walton CC, Hallock H, et al. Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology 2015. PMID: 26519540 

Dahm, K. Reinar, L M. Effekten av fysioterapi for pasienter med Parkinsons sykdom. Rapport fra Kunnskapssenteret nr 21 - 2009. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=25482182[uid]

Kordower JH. Gene therapy for Parkinson's disease: still a hot topic?. Neuropsychopharmacology 2015; 40(1): 255-6. pmid:25482182 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=26912295[uid]

Morizane A, Takahashi J. Cell therapy for Parkinson's disease. Neurol Med Chir (Tokyo) 2016; 56(3): 102-109. pmid:26912295 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=34215216[uid]

Liebert A, Bicknell B, Laakso EL, et al. Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study. BMC Neurol. 2021 Jul 2;21(1):256. PMID: 34215216 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=29570866[uid]

Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018 Aug; 33(8): 1248-1266. pmid:29570866 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=23432663[uid]

Hu XW, Qin SM, Li D, et al. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta Neurol Scand 2013; 128(2): 73-82. pmid:23432663 

Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson`s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013 Jul 23. PMID: 23781007. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=24616821[uid]

Morgan JC, Currie LJ, Harrison MB, et al. Mortality in levodopa-treated Parkinson's disease. Parkinsons Dis 2014; 2014: 426976. pmid:24616821 

Hva er årsaken til Parkinsons sykdom?

Del pasientinformasjon

Hjerneceller og dopamin

Hvorfor dør nevronene?

Parkinsons sykdom versus parkinsonisme

Vil du vite mer?